- Global industry experts in pulmonary diseases appointed: Marc Humbert, Steven Nathan, Oksana Shlobin, Vincent Cottin, Ardeschir Ghofrani, Joanna Pepke-Zaba and Luke Howard
- SAB will provide strategic and scientific perspectives to support development of Qureight’s AI imaging models for clinical trials in pulmonary hypertension
CAMBRIDGE, England--(BUSINESS WIRE)--Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has established a Scientific Advisory Board (SAB) focused on pulmonary hypertension (PH). The newly formed SAB, comprising globally recognised leaders in the field, will guide development of Qureight’s AI models in PH to advance clinical trials and accelerate the approval of novel therapeutics.
PH comprises a number of serious conditions defined by elevated pressure in the pulmonary circulation, where there is huge unmet need in terms of treatment. Monitoring PH is challenging and often relies on invasive right heart catheterisation to directly measure pressures. To support the development of a new generation of therapies for PH, there is demand for robust non-invasive ways to assess disease severity, stratify patients for trials, and detect treatment response over time. Qureight is developing its deep learning AI imaging models to support ongoing clinical trials in this space where there is a necessity for imaging, providing a reliable and non-invasive alternative approach to support and accelerate the approval of novel therapies.
Members of the newly appointed SAB include:
- Marc Humbert, MD, PhD, Dean of the Faculty of Medicine and Professor of Respiratory Medicine at the University Paris-Saclay and Inserm, France, and Director of the French Pulmonary Hypertension Reference Centre at the Assistance Publique Hôpitaux de Paris (AP-HP). Marc is a world-leading lung specialist and researcher who has devoted his career to deciphering the mechanisms of pulmonary arterial hypertension (PAH) and has built one of the world’s largest PH registries.
- Steven Nathan, MBBcH, FCCP, Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, Virginia, and Professor at Virginia Commonwealth University. Steven has served on multiple committees, including US Food and Drug Administration (FDA) advisory boards and steering committees for clinical trials in PH and idiopathic pulmonary fibrosis. He formerly served as Chair of the FDA Anesthesiology and Respiratory Therapy Devices Panel.
- Oksana Shlobin, MD, FCCP, Medical Director for the Pulmonary Hypertension Program and Director of Outreach and Education for the Inova Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, Virginia. Oksana is also an Associate Professor of Clinical Medicine at Georgetown University School of Medicine, Washington DC, and an Associate Clinical Professor of Medicine at the University of Virginia.
- Vincent Cottin, MD, PhD, Professor of Respiratory Medicine and coordinator of the National Reference Centre for Rare Pulmonary Diseases at the Louis Pradel Hospital and the Claude Bernard University Lyon 1, France. The centre has pioneered the clinical care and research of patients with rare lung disease and is the only centre in France recognised as part of the European Reference Center Network for interstitial lung diseases. Vincent is an investigator and member of the steering committee of numerous clinical trials and also currently serves as Associate Editor of the European Respiratory Journal.
- Professor Ardeschir Ghofrani, MD, Deputy Director of the Clinic, Chair of Pulmonary Vascular Medicine, and Professor of Pulmonary Vascular Research at the University Hospital Giessen and Marburg. Ardeschir is also a Visiting Professor for Pulmonary Vascular Medicine at Imperial College London and a founding member of the Pulmonary Vascular Research Institute (PVRI).
- Joanna Pepke-Zaba, PhD, FRCP, Consultant Chest Physician and previous Director of the National Pulmonary Hypertension Centre, Royal Papworth Hospital, Cambridge, UK. She was instrumental in the organisation of PH services in the UK, specifically the National Chronic Thromboembolic PH program. Joanna serves on various scientific, educational, international boards and societies as well as holding editorial duties. Her research focuses on translational programmes in PH, concentrating on chronic thromboembolic PH and idiopathic PAH. Joanna is also an Affiliated Associate Professor, University of Cambridge, UK.
- Professor Luke Howard, DPhil, FRCP, Consultant Pulmonologist and Lead Clinician in Cardiopulmonary Medicine at Imperial College Healthcare NHS Trust, specialising in pulmonary vascular disease, pulmonary embolism, unexplained breathlessness, and exercise physiology. Luke is also a Professor of Practice in Cardiopulmonary Medicine at the National Health and Lung Institute at Imperial College London.
Dr Simon Walsh, Chief Scientific Officer, Qureight, commented: “We are delighted to welcome these globally recognised leaders in pulmonary hypertension to our Scientific Advisory Board. Their insight will be instrumental as we advance our quantitative imaging models to address critical gaps in PH clinical trial design — particularly around non-invasive disease assessment, patient stratification, and treatment response monitoring. Our goal is to bring greater precision and biological clarity to PH trials, accelerating the development of much-needed therapies for patients.”
Contacts
For further information, please contact:
Zyme Communications
Katie Odgaard
Email: katie.odgaard@zymecommunications.com
Tel: +44 (0)7787 502 947
Qureight
Email: info@qureight.com
